Ticagrelor Market Analysis & Forecast: 2026-2033

Ticagrelor Market Size and Forecast – 2026 to 2033

The Ticagrelor Market is anticipated to grow at a CAGR of 7.4% with USD 2.1 Bn share in 2026 and is expected to reach USD 3.3 Bn in 2033. The rising prevalence of cardiovascular diseases, increasing cases of acute coronary syndrome and myocardial infarction, and a growing aging population drive the ticagrelor market. Cardiovascular diseases (CVDs) are the leading cause of death worldwide, accounting for approximately 19.2 million deaths annually.

Key Takeaways

• 60 mg hold the largest market share of 53.2% in 2026 owing to its growing prevalence of cardiovascular disease (CVD). According to the Centers for Disease Control and Prevention (CDC), cardiovascular disease caused 919,032 deaths in the United States in 2023, accounting for 1 in every 3 deaths.
• Acute Coronary Syndrome expected to hold largest market share of 54.4% in 2026 owing to the strong guideline recommendations. According to the American Heart Association, approximately 805,000 Americans experience an acute coronary syndrome (ACS) event each year.
• Hospital Pharmacies acquired the prominent market share of 43.3% in 2026 owing to its high hospitalization rates for acute coronary syndrome. Approximately 1.2 million people in the United States are hospitalized with acute coronary syndrome (ACS) each year.
• North America is expected to acquire the dominant share of 41.1% in 2026 owing to its high prevalence of cardiovascular disease.

Current Events and Their Impact on the Ticagrelor Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Request Free Sample

Why is 60mg Acquiring the Largest Market Share?

60mg hold the largest market share of 53.2% in 2026. The 60 mg ticagrelor segment grows because healthcare providers increasingly prescribe it for long-term secondary prevention of cardiovascular events in patients with a history of myocardial infarction who remain at high ischemic risk. Rising cases of coronary artery disease, an aging population, and improved survival following acute coronary syndrome continue to expand the eligible patient population. By 2030, one in six people worldwide will be aged 60 years or older. Strong clinical evidence, guideline recommendations for prolonged dual antiplatelet therapy in appropriate patients, better tolerability than higher doses, and wider availability of generic formulations further drive sustained demand for the 60 mg dosage. For instance, AstraZeneca announced that the US Food and Drug Administration (FDA) approved a new 60mg dose of BRILINTA (ticagrelor) tablets for patients with a history of heart attack who require treatment beyond the first year.

Acute Coronary Syndrome expected to hold largest market share 

To learn more about this report, Request Free Sample

Acute Coronary Syndrome expected to hold largest market share of 54.4% in 2026 owing to the superior clinical outcomes compared with clopidogrel. The acute coronary syndrome (ACS) segment drives the ticagrelor market as healthcare providers increasingly prescribe the drug to manage myocardial infarction and unstable angina. Ticagrelor is a P2Y12 platelet inhibitor indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS). Treatment is initiated with a 180 mg loading dose, followed by a 90 mg twice-daily maintenance dose administered with low-dose aspirin. Physicians prefer ticagrelor because it provides rapid platelet inhibition and has demonstrated strong clinical efficacy in reducing recurrent cardiovascular events. Rising adoption of percutaneous coronary intervention, expansion of emergency cardiac care services, and greater adherence to evidence-based treatment guidelines continue to strengthen demand. Increasing public awareness, earlier diagnosis, and ongoing investments in cardiovascular healthcare infrastructure further support the growth of this segment.

Which Distribution Channel segment dominates the market?

Hospital Pharmacies acquired the prominent market share of 43.3% in 2026. The hospital pharmacy segment drives the ticagrelor market because hospitals provide essential care for patients with acute coronary syndrome and those undergoing cardiac procedures. Rising cardiovascular disease prevalence, increasing hospital admissions, and greater use of percutaneous coronary intervention encourage healthcare providers to use ticagrelor in hospital settings. Hospitals ensure the availability of ticagrelor by following guideline-based treatment protocols and supporting rapid drug administration during emergency situations. Expanding cardiac care facilities and enhancing hospital pharmacy services continue to promote market growth.

Ticagrelor Market Trends

• Rising prevalence of cardiovascular diseases such as acute coronary syndrome (ACS), myocardial infarction, and coronary artery disease increases demand for advanced antiplatelet therapies like ticagrelor. Growing rates of hypertension, diabetes, obesity, and lifestyle-related risk factors continue to expand the patient population requiring cardiovascular event prevention. According to the U.S. Centers for Disease Control and Prevention (CDC), cardiovascular disease remains the leading cause of death in the United States, accounting for 919,032 deaths in 2023 (approximately 1 in every 3 deaths). Additionally, about 805,000 people experience a heart attack each year in the U.S., while coronary artery disease affects approximately 1 in 20 adults aged 20 years and older, highlighting the large patient population requiring antiplatelet therapies for secondary prevention.
• Increasing adoption of dual antiplatelet therapy (DAPT) strengthens ticagrelor utilization in ACS management. Healthcare providers increasingly use ticagrelor with aspirin following myocardial infarction and percutaneous coronary intervention (PCI) to reduce the risk of recurrent cardiovascular events and improve patient outcomes. The 2025 American Heart Association (AHA)/American College of Cardiology (ACC) Acute Coronary Syndrome Guideline recommends dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor for at least 12 months in ACS patients who are not at high bleeding risk. The guideline also recommends ticagrelor or prasugrel over clopidogrel for patients with ACS undergoing PCI, supporting continued clinical adoption of ticagrelor in guideline-directed care.

Regional Insights

To learn more about this report, Request Free Sample

North America dominates owing to ongoing clinical research and real-world evidence

North America is expected to acquire the dominant share of 41.10% in 2026. The North America ticagrelor market expands as healthcare providers address the growing burden of cardiovascular diseases, including acute coronary syndrome and coronary artery disease. Hospitals and cardiac centers leverage advanced healthcare infrastructure, increasing use of percutaneous coronary intervention and adherence to clinical guidelines to drive ticagrelor adoption. An aging population, greater awareness of cardiovascular risk management, and rising healthcare investments continue to increase demand. Established reimbursement systems, specialized cardiac facilities, and improved access to advanced therapies further support market expansion across the region. AstraZeneca announced the US pharmacy availability of BRILINTA™ (ticagrelor), an oral antiplatelet therapy approved by the FDA to reduce thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).

Asia Pacific Ticagrelor Market Trends

The Asia Pacific ticagrelor market grows as cardiovascular diseases become more prevalent, acute coronary syndrome cases increase, and awareness of advanced antiplatelet therapies expands. Healthcare providers strengthen market development by improving infrastructure, enhancing access to diagnostic services, and adopting innovative cardiovascular treatments. The region’s growing aging population, rising healthcare investments, and focus on better patient outcomes further drive demand for ticagrelor among healthcare professionals and patients. For instance, AstraZeneca Pharma India launched Brilinta (ticagrelor) after the DCGI approved its use in India for preventing heart attacks based on NDAC recommendations.

United States Ticagrelor Market Trends

The rising prevalence of cardiovascular diseases, including acute coronary syndrome and other heart-related conditions, drives the United States ticagrelor market. Healthcare providers increasingly adopt advanced antiplatelet therapies due to greater awareness, improved diagnosis, and evidence-based treatment practices. The country’s well-developed healthcare infrastructure, substantial healthcare expenditure, and ongoing pharmaceutical research activities strengthen market demand. Supportive reimbursement frameworks and a growing emphasis on preventing cardiovascular complications further promote the adoption of ticagrelor among patients.

Japan Ticagrelor Market Trends

Japan’s ticagrelor market grows as cardiovascular disease cases increase, healthcare providers recognize the benefits of advanced antiplatelet therapies, and patients require effective solutions to prevent thrombotic events. The aging population, rising incidence of lifestyle-related disorders, and enhanced healthcare infrastructure create favorable conditions for market development. Healthcare professionals increasingly adopt innovative cardiac care strategies, show greater preference for newer treatment options, and support ongoing research efforts that expand the use of ticagrelor in Japan.

Who are the Major Companies in Ticagrelor Industry

Some of the major key players in Ticagrelor are C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.

Key News

• In May 2025, Alembic Pharmaceuticals received U.S. FDA final approval for Ticagrelor Tablets 90 mg and tentative approval for Ticagrelor Tablets 60 mg through its Abbreviated New Drug Application (ANDA).

Market Report Scope

Analyst Opinion

• The ticagrelor market is primarily supported by the increasing clinical need for stronger antiplatelet management in acute coronary syndrome (ACS), rather than short-term prescribing trends. Cardiovascular disease remains the leading cause of death globally, with the World Health Organization estimating that cardiovascular conditions account for nearly 18 million deaths annually. In Japan and other developed markets, where aging populations face higher risks of coronary artery disease, physicians are increasingly prioritizing therapies that provide rapid platelet inhibition and reduce recurrent ischemic events.
• Ticagrelor’s competitive advantage is reinforced by strong clinical evidence from landmark trials. The PLATO trial demonstrated that ticagrelor reduced cardiovascular death, myocardial infarction, or stroke compared with clopidogrel in ACS patients, supporting its role as a preferred therapy in high-risk cardiovascular care. The drug’s faster and more reversible platelet inhibition profile gives it an edge in cases requiring immediate intervention, particularly among patients undergoing percutaneous coronary intervention (PCI).
• Adoption of ticagrelor will increasingly depend on healthcare systems balancing clinical outcomes with treatment costs. Real-world studies have shown that medication adherence remains a key challenge in long-term antiplatelet therapy, with discontinuation rates affecting treatment effectiveness. However, growing emphasis on secondary prevention, improved cardiovascular diagnosis, and guideline-driven use of dual antiplatelet therapy will continue to strengthen demand for ticagrelor, especially in markets with advanced cardiac care infrastructure.

Market Segmentation

• By Strength (Revenue, USD Bn, 2021-2033)
  • 60 mg
  • 90 mg
• By Indication (Revenue, USD Bn, 2021-2033)
  • Acute Coronary Syndrome
  • Ischemic Stroke
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research interviews

• Cardiologists, interventional cardiologists, and healthcare specialists
• Hospital procurement managers and pharmacy directors
• Pharmaceutical distributors and supply chain professionals
• Regulatory and healthcare policy experts
• Industry stakeholders involved in antiplatelet therapy development and commercialization

Databases

• Clinical trial databases
• Regulatory approval databases
• Government healthcare databases
• Drug safety and pharmacovigilance databases
• Patent and intellectual property databases
• Healthcare utilization and prescription databases

Magazines

• Pharmaceutical industry magazines
• Healthcare technology magazines
• Cardiology-focused publications
• Medical innovation and biotechnology magazines

Journals

• Peer-reviewed cardiology journals
• Pharmacology and therapeutics journals
• Clinical research journals
• Cardiovascular medicine journals
• Drug development and safety journals

Newspapers

• Healthcare and life sciences news publications
• Business and financial newspapers
• Medical research news platforms
• Regulatory and policy news sources

Associations

• Cardiology associations
• Pharmaceutical and biotechnology associations
• Healthcare professional organizations
• Medical research organizations
• Patient advocacy and cardiovascular health organizations

Public Domain sources

• Government health agencies and regulatory authority publications
• Clinical trial registries
• Public healthcare reports and statistics
• Academic research repositories
• Drug approval and safety assessment documents
• Open-access scientific publications

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years